3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
44
Pancreatic Neoplasms
37
Carcinoma, Non-Small-Cell Lung
37
Triple Negative Breast Neoplasms
28
Ovarian Neoplasms
20
Fallopian Tube Neoplasms
19
Lung Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
13
Neoplasm Metastasis
11
Uterine Cervical Neoplasms
8
Melanoma
7
Inflammatory Breast Neoplasms
7
Esophageal Squamous Cell Carcinoma
6
Breast Neoplasms, Male
6
Stomach Neoplasms
5
Cholangiocarcinoma
5
Brenner Tumor
5
Pancreatic Adenocarcinoma
4
Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Transitional Cell
4
Adenocarcinoma, Bronchiolo-Alveolar
4
Adenocarcinoma of Lung
4
Adenocarcinoma Of Esophagus
4
Urinary Bladder Neoplasms
3
Pleural Effusion, Malignant
3
Oropharyngeal Neoplasms
3
Nasopharyngeal Carcinoma
3
Mouth Neoplasms
3
Endometrial Neoplasms
3
Interventions
cabazitaxel
3
Trastuzumab
3
Cyclophosphamide
2
Cetuximab
2
Carboplatin
2
Aspirin
2
ribociclib
1
pertuzumab
1
eribulin
1
Thiotepa
1
Taxes
1
Stem Cell Transplantation
1
Propofol
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liquid Biopsy
1
Letrozole
1
Ipilimumab
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Gemcitabine
1
Fulvestrant
1
Epirubicin
1
Docetaxel
1
Denosumab
1
Circulating Tumor DNA
1
Cell-Free Nucleic Acids
1
CA-72-4 antigen
1
CA-19-9 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplastic Cells, Circulating
×
Taxes
×
Clear all
NCT02707159
2023-03-08
PACT-ACT-v6
Helse Stavanger HF
Phase 2
Completed
70 enrolled